Skip to main content
. 2022 Oct 13;36:103228. doi: 10.1016/j.nicl.2022.103228

Table 2.

Demographics for people with RRMS with complete data at M0 (baseline) and follow-up (M12). DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale score; ICV: intracranial volume; WML: white matter lesions.

Magnetisation transfer imaging NODDI ISOVF / ICVF & g-ratio
n (F:M) 62 (48:14) 60 (46:14)
Mean age [range] in years at M0 37.6 [21.7 to 67.3] 37.8 [22.3 to 67.3]
Median EDSS at M0 [range] 2 [0 to 6] 2 [0 to 6]
Median EDSS at M12 [range] 2.5 [0 to 6.5] 2.75 [0 to 6.5]
Number of patients with DMT initiated by M12 38 (61.3 %) 36 (60.0 %)
Mean number of days between diagnosis and M0 [range] 68 [7 to 171] 69 [8 to 171]
Median time since physician-reported first symptom onset in years [range] 3.6 [0.2 to 33.2] (2 missing) 3.55 [0.2 to 33.2] (2 missing)
Median WML volume (as % of ICV) at M0 [range] 0.572
[0.041 to 2.628]
0.572 [0.041 to 2.628]
Median change in WML volume over 1 year (as % of ICV, abs. diff) [range] 0.165 [0.028 to 0.592] 0.165 [0.028 to 0.592]